Effective Strategies and Clinical Updates in
Pulmonary Arterial Hypertension

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Spring Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 15, 2017 to August 1, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by educational grants from
Actelion Pharmaceuticals US Inc., Bayer Healthcare Pharmaceuticals, and Gilead Sciences

Description:
Though relatively rare – affecting approximately six per one million people – PAH is a very serious, life threatening condition that worsens over time and for which there is no cure. Approximately half of people diagnosed with PAH will not live past five years, while those with untreated PAH have an average survival expectancy of approximately three years following diagnosis – and even with aggressive management, PAH has a 15% annual mortality rate. Associated treatment costs have risen with the expansion of treatment options, ranging from $18,000 to $244,000 annually per patient. Additionally, PAH often leads to the onset of co-morbidities associated with the disease, which not only puts the patient at higher risk but also increases the costs to the healthcare system. Early diagnosis and accurate classification are keys to managing costs. Emerging treatments, including prostanoids, are changing the way patients are being treated and clinicians need to understand how to apply treatment algorithms accordingly for pharmacologic decisions.

Upon Completion of this activity, participants will be able to:

  • Identify the latest recommendations and clinical guidelines for the management of patients with PAH

  • Explore the advances in the diagnostic algorithm for pulmonary hypertension

  • Evaluate the latest data on oral prostanoids and how they can be incorporated into appropriate treatment plans

  • Discuss effective therapeutic strategies to modify treatment for patients with worsening PAH despite existing therapy

  • Analyze the differences between conventional and emerging PAH therapies based on current evidence for their efficacy, safety, and utility
     

Faculty: Harrison Farber, MD
Professor of Medicine
Director
Pulmonary Hypertension Center
Boston Medical Center, Boston University

Disclosure:

Dr. Farber serves on advisory board/panel for Actelion, Bayer, Bellerophon, Gilead and United Therapeutics. He receives grant/research support from Actelion and serves on the speakers bureau for Actelion, Bayer & Gilead. His presentation has been peer reviewed.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation

The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.  Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This educational activity is supported by educational grants from
Actelion Pharmaceuticals US Inc., Bayer Healthcare Pharmaceuticals, and Gilead Sciences

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue